The 71st annual American College of Cardiology’s Scientific Session saw several wins – and some “mehs” led by some of biopharma’s largest companies, according to BioSpace.
A new study by the American Stroke Association found that the risk of stroke in adults with COVID-19 between the ages of 65 to 74 was highest the first three days after diagnosis. Additionally, investigators at the National Institutes of Allergy and Infectious Diseases’ Vaccine Research Center ran tests on primates and found that updating COVID-19 vaccines to focus on the Omicron variant may not provide much benefit.
More than 55 million people worldwide are living with dementia, a neurological disorder that robs them of their memory and costs the world $1.3 trillion a year, the World Health Organization (WHO) said on Sept. 2.
The U.S. Food and Drug Administration approved Abbott’s Amplatzer Amulet Left Atrial Appendage Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke.
Light-to-moderate alcohol consumption is linked to a reduced risk of heart attack, stroke and death among those with heart disease, according to a study published in the journal BMC Medicine on July 26.
The European Commission granted Amarin Corporation Plc’s fish-oil derived heart drug Vazkepa marketing authorization in the European Union, the drugmaker said on March 30.
A judge in Hawaii ordered Bristol-Myers Squibb Co. and Sanofi SA to pay more than $834 million to the state for failing to warn non-white patients properly of health risks from the blood thinner Plavix.
In a Reuters roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, common cold antibodies yield clues to Covid-19 behavior.
AstraZeneca’s Brilinta (ticagrelor) was approved by the U.S. Food and Drug Administration to reduce the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack.
Anthos Therapeutics is developing next-generation anticoagulants that do not have the bleeding risks that current blood thinners have.